21:27 , Jun 11, 2019 |  BC Extra  |  Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

With a Phase III readout imminent for Deciphera's kinase switch control inhibitor ripretinib in GIST, Zai Lab has obtained the compound's rights in Greater China, adding to a planned gastric cancer franchise it has built...
19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
23:20 , Jun 3, 2019 |  BC Extra  |  Clinical News

June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more

Celgene highlights iberdomide data for MM at ASCO  Celgene Corp. (NASDAQ:CELG) presented data at ASCO Sunday showing that iberdomide (CC-220) plus dexamethasone led to an overall response rate (ORR) of 32%, including 17 partial responses...
22:34 , Apr 22, 2019 |  BC Extra  |  Company News

Management tracks: MeiraGTx, Retrophin, Aduro

MeiraGTx Holdings plc (NASDAQ:MGTX) said Katherine Breedis stepped down as CFO on April 16, a little over six months after she joined the gene therapy company. MeiraGTx said COO Richard Giroux will take on the...
23:21 , Apr 11, 2019 |  BC Extra  |  Company News

Management tracks: Prime, Flexion, NodThera, Imara

PBM Prime Therapeutics LLC (Eagan, Minn.) hired Kenneth Paulus as president and CEO, effective May 7. Paulus is an executive adviser at Water Street Healthcare Partners. In 2005-15, Paulus held leadership roles at Minneapolis-based non-profit...
22:23 , Apr 2, 2019 |  BC Extra  |  Politics & Policy

Scrutiny over insulin pricing intensifies in Washington

Congressional scrutiny over insulin prices is intensifying as Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-Ore.) asked three PBMs to explain their role in pricing insulin products. In letters to...
23:09 , Mar 12, 2019 |  BC Extra  |  Politics & Policy

Senators call on PBMs to testify next on drug pricing

Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-Ore.) invited five PBMs to testify on April 3 at its third hearing to discuss drug pricing. Invited PBMs include Cigna Corp. (NYSE:CI);...
23:44 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
19:00 , Jan 18, 2019 |  BC Week In Review  |  Company News

Five Prime cuts headcount by 20%

Five Prime Therapeutics Inc. (NASDAQ:FPRX) said it will reduce headcount by 41 (20%). Cuts will come from research, pathology and manufacturing. The cancer company’s pipeline includes five programs. Its lead compound, bemarituzumab, is in Phase...
00:00 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Patient sample and mouse studies suggest depleting microglia with CSF1R inhibitors could help treat chemotherapy-induced neurological dysfunction. In postmortem frontal lobe tissue samples from pediatric and young adult patients treated with methotrexate and...